1-3 of 3
Timothy C. Burn
Close
Sort by
Journal Articles

The effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden in patients with myelofibrosis

Clinical Trials & Observations Brief Report
Michael Deininger, Jerald Radich, Timothy C. Burn, Reid Huber, Dilan Paranagama, Srdan Verstovsek
Journal: Blood
Blood (2015) 126 (13): 1551–1554.
https://doi.org/10.1182/blood-2015-03-635235
Published: 2015
Includes: Supplemental data
Journal Articles

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish, Gengjie Yang, Qian Wang, Kathy Wang, Lynn Leffet, Michael J. Hansbury, Beth Thomas, Mark Rupar, Paul Waeltz, Kevin J. Bowman, Padmaja Polam, Richard B. Sparks, Eddy W. Yue, Yanlong Li, Richard Wynn, Jordan S. Fridman, Timothy C. Burn, Andrew P. Combs, Robert C. Newton, Peggy A. Scherle
Journal: Blood
Blood (2010) 115 (17): 3520–3530.
https://doi.org/10.1182/blood-2009-09-246124
Published: 2010
Journal Articles

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

Priya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, Sachie Marubayashi, Jay Patel, Aviva Goel, Nicole Kucine, Jeffrey R. Gardner, Andrew P. Combs, Kris Vaddi, Patrick J. Haley, Timothy C. Burn, Mark Rupar, Jacqueline F. Bromberg, Mark L. Heaney, Elisa de Stanchina, Jordan S. Fridman, Ross L. Levine
Journal: Blood
Blood (2010) 115 (14): 2919–2927.
https://doi.org/10.1182/blood-2009-04-218842
Published: 2010
Includes: Supplemental data